TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05081219

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin (Humulin® R U-100)
Description: Participants will administer 40 IU of Humulin® U-100 insulin four times per day with an intranasal delivery device.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin (Humulin® R U-100)
Description: Participants will administer 40 IU of Humulin® U-100 insulin four times per day with an intranasal delivery device.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Empagliflozin 10 MG
Description: Participants will be assigned to receive Empagliflozin 10 mg capsules to be taken by mouth once daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Empagliflozin 10 MG
Description: Participants will be assigned to receive Empagliflozin 10 mg capsules to be taken by mouth once daily.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Aptar Pharma CPS Intranasal Delivery Device
Description: Participants will be assigned to receive Humulin® insulin or placebo administered through the Aptar Pharma CPS intranasal delivery device.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Aptar Pharma CPS Intranasal Delivery Device
Description: Participants will be assigned to receive Humulin® insulin or placebo administered through the Aptar Pharma CPS intranasal delivery device.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Aptar Pharma CPS Intranasal Delivery Device
Description: Participants will be assigned to receive Humulin® insulin or placebo administered through the Aptar Pharma CPS intranasal delivery device.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Aptar Pharma CPS Intranasal Delivery Device
Description: Participants will be assigned to receive Humulin® insulin or placebo administered through the Aptar Pharma CPS intranasal delivery device.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo (Insulin Diluent)
Description: Participants will administer placebo (insulin diluent) four times per day with an intranasal delivery device.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (Insulin Diluent)
Description: Participants will administer placebo (insulin diluent) four times per day with an intranasal delivery device.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo (Capsules)
Description: Participants will be assigned to receive placebo capsules (Empagliflozin 10 mg) to be taken by mouth once daily.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (Capsules)
Description: Participants will be assigned to receive placebo capsules (Empagliflozin 10 mg) to be taken by mouth once daily.
Study: NCT06668922

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Inulin
Description: Inulin ingestion is not being used to diagnose, treat, or prevent IBS. Inulin is being used to study an individual's ability to ferment dietary fiber.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Inulin
Description: Inulin ingestion is not being used to diagnose, treat, or prevent IBS. Inulin is being used to study an individual's ability to ferment dietary fiber.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Inulin
Description: Inulin ingestion is not being used to diagnose, treat, or prevent IBS. Inulin is being used to study an individual's ability to ferment dietary fiber.
Study: NCT05505942

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: LPA Sessions
Description: A study interventionist will conduct phone/video sessions and provide information regarding the acute and long-term psychological and physical benefits of increasing PA. Participants will be introduced to the concept of utilizing brief bouts of PA as a coping strategy for managing emotions and urges to drink alcohol in-the-moment. Participants will also be given information on the public health guidelines for PA (and how these translate into step counts) as well as how to determine if their PA is moderate intensity (e.g., measuring heart rate and identifying rate of perceived exertion). Study clinicians will also orient participants to the proper use of the Fitbit activity tracker and tips for self-monitoring step counts with the tracker and on the app and/or website.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Fitbit Only
Description: Interventionists will provide participants information about the proper use of the Fitbit activity tracker and offer tips for self-monitoring step counts with the tracker and on the app and/or website.
Study: NCT04710264

Intervention type: OTHER
Intervention: AURORA-Rec
Description: Explorative study of cumulus cells gene expression in relation to the patient treatment and oocyte competence.

Intervention type: OTHER
Intervention: AURORA-Rec
Description: Explorative study of cumulus cells gene expression in relation to the patient treatment and oocyte competence.
Study: NCT05875571

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketorolac
Description: Patients will get IV ketorolac during IUD placement under sedation

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients will get IV placebo during IUD placement under sedation
Study: NCT05862831

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PM1003 Injection
Description: Subjects will receive PM1003 by intravenous administration.
Study: NCT04757103

Intervention type: PROCEDURE
Intervention: Resection of the retrorectal tumor
Description: Surgical resection of the retrorectal mass

Intervention type: PROCEDURE
Intervention: Resection of the retrorectal tumor
Description: Surgical resection of the retrorectal mass
Study: NCT05543811

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Food for special dietary use
Description: Food for special dietary use (spread) with modified ingredients' content will be included to the diet of 70 patients without significant organic pathology for 14 days receiving standard diet, modified by the inclusion of two portions of the spread, 20 grams each for breakfast and dinner

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Food for special dietary use
Description: Food for special dietary use (spread) with modified ingredients' content will be included to the diet of 70 patients without significant organic pathology for 14 days receiving standard diet, modified by the inclusion of two portions of the spread, 20 grams each for breakfast and dinner
Study: NCT05273281

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transabdominal plane block
Description: Peripheral nerve block

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Quadratus lumborum block
Description: Peripheral nerve block
Study: NCT05931107

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Stress ball practice group (Stress ball squeezing)
Description: The stress ball is made of round, colorful, high-quality silicone. A stress ball of medium hardness and 6 cm in diameter (suitable for adult use) will be used in the research. When it is loosened, it returns to its original state. In the experimental group, the patients are required to squeeze the ball once after counting to three, inhale each time they squeeze the ball, exhale when they loosen their grip, and focus only on the ball. The experimental group has to squeeze the stress ball for 10-15 minutes every day for 4 weeks.
Study: NCT04247711

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: OTCH
Description: OTCH is structured in three phrases (i. engagement and initial needs assessment, ii. ongoing intervention and monitoring, and iii. transition to long-term services) and lasts an average of two years. OTCH will maintain the central characteristics of the OnTrack model, as well as its core principles, which include (1) Person-centered care, (2) Shared decision-making, (3) Recovery orientation, and (4) Culturally-competent care.
Study: NCT05568823

Intervention type: OTHER
Group type: OTHER
Intervention: Blood sampling
Description: Measurement of markers of disease evolution
Study: NCT06174402

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fenofibrate
Description: Fenofibrate 200 mg/day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 tablet/ day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: UDCA
Description: UDCA 13-15mg/kg/day
Study: NCT06125561

Intervention type: OTHER
Intervention: Probing depth and Clinical attachment loss
Description: CPTIN probe will be used for the clinical examination

Intervention type: OTHER
Intervention: Probing depth and Clinical attachment loss
Description: CPTIN probe will be used for the clinical examination
Study: NCT05661123

Intervention type: OTHER
Group type: OTHER
Intervention: Complete decongestive therapy
Description: 1. Education.~2. Skin care .~3. Pneumatic compression device .~4. Manual lymph draining .~5. Multilayer short stretch compression bandages.~6. Exercises.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Complete decongestive therapy
Description: 1. Education.~2. Skin care .~3. Pneumatic compression device .~4. Manual lymph draining .~5. Multilayer short stretch compression bandages.~6. Exercises.
Study: NCT05344365

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iloperidone
Description: oral tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iloperidone
Description: oral tablet
Study: NCT04784039

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Transesophageal echocardiography
Description: Patients randomized to the TEE group will be scheduled for cardioversion with prior TEE

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: D-Dimer analysis
Description: Patients randomized to the DD-group will be scheduled for cardioversion with prior D-Dimer analysis. In case of positive D-Dimer results, TEE will be performed prior to cardioversion
Study: NCT04567498

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: exhaled breath sampling
Description: The participants are requested to quietly sit and breathe to the air collecting bag until the collecting bag is full. The collecting bag is sealed and connected to the e-nose machine via a collecting hose and HEPA-filter. The data are read and stored in the e-nose machine.
Study: NCT04247711

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Usual FEP Services
Description: These include services such as psychiatric medication, psychotherapy, and psychoeducation for people with FEP and are usually provided at outpatient mental health clinics.
Study: NCT06174402

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: UDCA
Description: UDCA 13-15mg/kg/day
Study: NCT06422767

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bepirovirsen
Description: Bepirovirsen will be administered.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered.
Study: NCT05435014

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: T-ACE Oil
Description: TAE/TACE treatment was performed with T-ACE Oil. The volume of T-ACE Oil injected would be 1-1.5 mL/cm based on the diameter (cm) of the treated tumor. The maximum dose is 0.25 mL/kg/day but not over 15 mL for each treatment.
Study: NCT06457958

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sevoflurane Group
Description: Preoperative: One hour before surgery, a blood sample will be taken. Intraoperative: Sevoflurane will be used as the inhalational anesthetic. Routine general anesthesia procedures will be followed. Sevoflurane consumption, oxygen levels, and vital parameters will be recorded.~Postoperative: One hour after extubation, another blood sample will be taken, marking the end of patient monitoring.~Laboratory Analysis: Blood samples will be stored in the biochemistry laboratory. Hemoxygenase-1 protein levels will be measured by ELISA, and mRNA expression will be analyzed using PCR.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Desflurane Group
Description: Preoperative: One hour before surgery, a blood sample will be taken. Intraoperative: Desflurane will be used as the inhalational anesthetic. Routine general anesthesia procedures will be followed. Desflurane consumption, oxygen levels, and vital parameters will be recorded.~Postoperative: One hour after extubation, another blood sample will be taken, marking the end of patient monitoring.~Laboratory Analysis: Blood samples will be stored in the biochemistry laboratory. Hemoxygenase-1 protein levels will be measured by ELISA, and mRNA expression will be analyzed using PCR.
Study: NCT04631692

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Health literacy intervention
Description: We will translate and adapt an intervention developed by Ferreira et al. to address health literacy and improve CRC screening. This intervention combined a 2-hour health literacy training targeting primary care physicians (which also included information about CRC screening) and a patient level intervention that consisted of a brochure and video.~In order to promote generalizability, large-scale diffusion, dissemination and sustained use beyond the funded-research period, we will use blended learning to develop a 2-hour e-learning health literacy training in French and a one-hour booster session.~The patient-facing intervention (video + brochure) will follow key plain language and health literacy principles to translate evidence-based information in content that all patients can understand. Existing materials developed in France will be used and adapted as relevant.
Study: NCT05193708

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Windowed Bonding
Description: A 3D printed tray/guide with open window for the orthodontic brackets

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Digital Indirect bonding tray
Description: Vacuum formed on a 3d printer cast with brackets
Study: NCT06152172

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KYV-101
Description: The KYV-101 will be administered IV as a single infusion dosed at 1×108 CAR+ T cells.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KYV-101
Description: The KYV-101 will be administered IV as a single infusion dosed at 1×108 CAR+ T cells.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KYV-101
Description: The KYV-101 will be administered IV as a single infusion dosed at 1×108 CAR+ T cells.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KYV-101
Description: The KYV-101 will be administered IV as a single infusion dosed at 1×108 CAR+ T cells.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Lymphodepleting chemotherapy of cyclophosphamide (CYC) 300 mg/m2
Study: NCT05993819

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pilates based core stability training and congnitive therapy
Description: Exercises were structured in different conditions such as supine, side-lying, prone, quadruped, sitting, and standing positions. The various variations of each exercise were created so that the easier or more difficult versions of the exercises were selected according to the level of the patients, basically in the same training plan for all.the patients also will receive cognitive behavioural therapy.The CBT manual was written specifically for this trial. The sessions were collaborative in style, and the therapist used Socratic questioning wherever possible. The main aim was to challenge any behavioral, cognitive, emotional and external factors that may be contributing to MS fatigue.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pilates based core stability training
Description: Exercises were structured in different conditions such as supine, side-lying, prone, quadruped, sitting, and standing positions. The various variations of each exercise were created so that the easier or more difficult versions of the exercises were selected according to the level of the patients, basically in the same training plan for all. The exercises were gradually made more difficult to increase the stabilization of the trunk by gradually reducing the support surface, increasing the extremity loading, and adding various materials.Exercises were progressed every 2 weeks in both groups and were performed with 10 repetitions for the first 4 weeks and 15 repetitions for the next 4 weeks.
Study: NCT04232254

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Animal-based Protein Foods
Description: Participants will consume animal-based protein foods.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Animal-based Protein Foods
Description: Participants will consume animal-based protein foods.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Skewed Protein Distribution
Description: Participants will consume 3 meals per day consisting of 10-, 30-, 60% of dietary protein for breakfast, lunch, and dinner, respectively.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Skewed Protein Distribution
Description: Participants will consume 3 meals per day consisting of 10-, 30-, 60% of dietary protein for breakfast, lunch, and dinner, respectively.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Plant-based Protein Foods
Description: Participants will consume plant-based protein foods.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Plant-based Protein Foods
Description: Participants will consume plant-based protein foods.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Balanced Protein Distribution
Description: Participants will consume 5 meals per day consisting of 20% of dietary protein per meal.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Balanced Protein Distribution
Description: Participants will consume 5 meals per day consisting of 20% of dietary protein per meal.
Study: NCT06469593

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Automated insuling delivery system
Description: Closed-loop insulin pumps including MiniMed 780G, Tandom T2-slim x2 and YpsoCamAPS

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Automated insuling delivery system
Description: Closed-loop insulin pumps including MiniMed 780G, Tandom T2-slim x2 and YpsoCamAPS
Study: NCT04803539

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: capecitabine
Description: capecitabine is proved to improve 5-year disease-free survival among women with early-stage triple-negative breast cancer who received standard adjuvant treatment(The SYSUCC-001 Randomized Clinical Trial)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: capecitabine + camrelizumab + apatinib
Description: Camrelizumab combined with apatinib is a safe and effective combination proved in patients with advanced TNBC in our early study
Study: NCT04880733

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Acupuncture for pain management
Description: A manualized acupuncture protocol will be performed by a licensed acupuncturist in the patient's emergency department room.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Usual care for pain management
Description: Patient will receive usual care for pain management.
Study: NCT06289569

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Home telerehabilitation therapy
Description: Occupational therapist prescribed hand/arm exercises will be assigned to patients. Records of each subject's motor tasks, number of repetition and level of performance will be kept. Standard of care home therapy will be performed Monday-Friday for approximately 4 weeks, followed by 4 weeks of application-driven home teletherapy. It is expected that approximately 20 treatments will be finished in 4weeks, however the amount of therapy completed will be recorded to accommodate patients' schedules. Treatment times can be broken up into multiple treatment periods to accommodate patient and caregiver preferences.
Study: NCT05406141

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Amino acid formula (Neocate Jr)
Description: Use Neocate Jr for 4 weeks, either as sole source of nutrition or oral nutritional supplement:~* Sole source of nutrition: as far as possible \>7 days, especially newly diagnosed allergy children~* Oral nutritional supplement (Neocate Jr ≥50% of daily total energy and the rest provided by food)
Study: NCT05095454

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Percutaneous epidural electrical spinal stimulation
Description: Abbott percutaneous trial lead for epidural neurostimulation (Model 3086)~Ripple Neuromed Nomad Neurostimulation System

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical spinal stimulation
Description: Digitimer DS8R Bipolar Constant Current Stimulator
Study: NCT04880733

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual care for pain management
Description: Patient will receive usual care for pain management.
Study: NCT05435014

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lipiodol
Description: TAE/TACE treatment was performed with Lipiodol. The volume of Lipiodol injected would be 1-1.5 mL/cm based on the diameter (cm) of the treated tumor. The maximum dose is 0.25 mL/kg/day but not over 15 mL for each treatment.
Study: NCT06152172

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Lymphodepleting chemotherapy of cyclophosphamide (CYC) 300 mg/m2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Lymphodepleting chemotherapy of cyclophosphamide (CYC) 300 mg/m2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Lymphodepleting chemotherapy of cyclophosphamide (CYC) 300 mg/m2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Lymphodepleting chemotherapy of Fludarabine (FLU) 30 mg/m2 intravenously (IV)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Lymphodepleting chemotherapy of Fludarabine (FLU) 30 mg/m2 intravenously (IV)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Lymphodepleting chemotherapy of Fludarabine (FLU) 30 mg/m2 intravenously (IV)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Lymphodepleting chemotherapy of Fludarabine (FLU) 30 mg/m2 intravenously (IV)
Study: NCT06616987

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sacituzumab Govitecan with pegfilgrastim
Description: ▪ Sacituzumab Govitecan group~- Sacituzumab Govitecan 10mg/kg IV on CnD1 and D8 + Pegfilgrastim 6mg SC QD on CnD9